Pujante Alarcón Pedro, Alonso Felgueroso Carlos, Ares Blanco Jessica, Morales Sánchez Paula, Lambert Goitia Carmen, Rodríguez Escobedo Raúl, Rodríguez Rodero Sandra, Delgado Alvarez Elías, Menéndez Torre Edelmiro Luis
Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
Servicio de Endocrinología y Nutrición, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
Endocrinol Diabetes Nutr (Engl Ed). 2022 Aug-Sep;69(7):493-499. doi: 10.1016/j.endien.2022.08.001. Epub 2022 Aug 23.
Despite continuous glucose monitoring having been proven useful in patients with type 1 diabetes mellitus, A1C remains the gold standard for assessing disease management.
Descriptive, retrospective study which included 252 patients, 40.5% male, mean age 44.91±14.57 years, mean duration of diabetes 22.21±13.12 years, 88.1% on basal-bolus insulin therapy and 11.9% users of continuous subcutaneous insulin infusion. Glucose measurement, analytical and anthropometric data were obtained.
The mean time in range was 60.18±15.60% and was associated with A1C after adjusting for age, gender, duration of diabetes, BMI, insulin regimen, %CV and time below range (ß: -0.548; p<0.01). The glucose management indicator (GMI) was 7.19±0.69% and was also associated with A1C (ß: 0.957; p<0.01) regardless of age, gender, duration of diabetes, BMI, insulin treatment, %CV and time in range. The average difference between A1C and GMI was 0.17±0.65% (-2.70-3.40%), being higher as A1C increased, in a linear and significant manner, without being influenced by the duration of diabetes or CV.
Although we found a positive correlation between continuous glucose monitoring glucose measurement parameters and A1C, there is still not enough evidence to replace one parameter with another.
尽管连续血糖监测已被证明对1型糖尿病患者有用，但糖化血红蛋白（A1C）仍然是评估疾病管理的金标准。
描述性回顾性研究，纳入252例患者，男性占40.5%，平均年龄44.91±14.57岁，平均糖尿病病程22.21±13.12年，88.1%接受基础-餐时胰岛素治疗，11.9%使用持续皮下胰岛素输注。获取了血糖测量、分析和人体测量数据。
血糖达标时间平均为60.18±15.60%，在调整年龄、性别、糖尿病病程、体重指数（BMI）、胰岛素治疗方案、血糖变异系数（%CV）和血糖低于目标范围的时间后，与A1C相关（β：-0.548；p<0.01）。血糖管理指标（GMI）为7.19±0.69%，无论年龄、性别、糖尿病病程、BMI、胰岛素治疗、%CV和血糖达标时间如何，也与A1C相关（β：0.957；p<0.01）。A1C与GMI的平均差值为0.17±0.65%（-2.70 - 3.40%），随着A1C升高呈线性且显著增加，不受糖尿病病程或CV的影响。
尽管我们发现连续血糖监测的血糖测量参数与A1C之间存在正相关，但仍没有足够证据用一个参数替代另一个参数。
